Firefly Neuroscience Inc (NASDAQ:AIFF) shares are trading sharply higher Friday after the company said it had advanced research that may enable clinicians to distinguish among the three main subtypes of attention-deficit/hyperactivity disorder using brain scans collected on its FDA-510(k)-cleared Evoke System. Here’s what investors need to know.
- Firefly Neuroscience stock is surging to new heights today. Why is AIFF stock surging?
Firefly Advances Objective Brain-Based ADHD Diagnosis Tools
According to Firefly, the work uses Resting EEG and Cognitive EEG, also known as ERP, to identify potential neural biomarkers tied to hyperactive-impulsive, inattentive and combined ADHD presentations.
The announcement is significant because ADHD is typically diagnosed using symptom-based assessments rather than objective biological tools.
Firefly said its approach could eventually complement traditional checklists with brain-based data, helping clinicians tailor treatment choices, guide dosage decisions and monitor whether a therapy is working at the neurological level.
Firefly Targets $10 Billion U.S. ADHD Treatment Market
Firefly said the opportunity is sizable, pointing to a U.S. ADHD treatment market estimated at more than $10 billion. The company also said the research supports its broader strategy of building what it describes as the world’s first EEG/ERP brain foundation model, trained on a database of more than 191,000 brain scans.
Management added that the biomarker discovery underscores the company’s push to use AI-powered brain analytics to improve diagnosis and treatment monitoring across neurological and psychiatric conditions.
AIFF RSI Surges Into Overbought Territory
Firefly Neuroscience’s RSI has recently surged above 70, indicating the stock has entered overbought territory following a sharp upward move.
Over the past year, AIFF’s RSI mostly fluctuated within the neutral range (30–70) with occasional dips into oversold levels before the latest spike.
AIFF Surges Friday Afternoon
AIFF Price Action: Firefly Neuroscience shares were up 47.70% at $2.57 at the time of publication on Friday, according to Benzinga Pro data.
Image: Shutterstock
Recent Comments